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INTRODUCTION
Attention-deficit hyperactivity disorder (ADHD) is 
a frequent neurodevelopmental disorder with an in-
creasing prevalence over the last 2 decades [1]. A recent 
cohort study of almost 7.5 million people with roughly 
700,000 prescriptions, reported an increase in prescrip-
tion rate from 42.7 prescriptions per 10,000 persons 
before the year 2000 to 394.4 prescriptions in 2015 an 
increase of about 800% in prescription rate [2]. The up-
surge was observed in both sexes and in all age groups. 
Moreover, unlike previous trends of increased diagnosis 
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Purpose: To evaluate the in vitro impact of ritalinic acid (RA), a major metabolite of methylphenidate (drug to treat attention-
deficit hyperactivity disorder), on sperm motility, vitality and oxidative stress.
Materials and Methods: Semen samples (n=13) were collected from healthy donors and a semen analysis was performed 
according to World Health Organization. Density gradient centrifugation was performed to isolate motile sperm. Samples 
were incubated with different concentrations (0, 1, 10, 100, and 1,000 ng/mL) of RA. The non-exposed group (0 ng/mL) was 
defined as the control group. Samples were analyzed for motility at different time points (0, 60, 150, 240, and 300 minutes) 
and for vitality and oxidation reduction potential (ORP) (at 0, 240, and 300 minutes). Sperm motility was assessed manually 
and motion kinetic parameters were recorded by computer aided semen analysis. 
Results: RA at any tested concentration significantly increased sperm motility compared to the control in a time-dependent 
manner with a maximum increase after 240 minutes. Motion kinetic parameters were not comparable. For sperm vitality, 
supplementation with RA significantly maintained survival at higher levels, while non-treated sperm gradually died. These 
higher levels of vitality were maintained with rising RA concentrations of up to 1,000 ng/mL. A non-significant trend of in-
creased ORP was observed in all study groups.
Conclusions: RA increases sperm motility and maintains vitality at any concentration tested. Therefore, RA might be utilized 
to improve sperm quality in asthenozoospermic specimens. However, further investigation is ongoing to evaluate the effect of 
RA on other sperm parameters.
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and treatment of ADHD in pre-school and school aged 
children, the later increase applies to children, adoles-
cents, and even adults [3]. 
The most commonly used first line pharmacologic 
treatment for ADHD is methylphenidate (MPH). The 
mechanism of action of MPH in ADHD is still a mat-
ter of debate, but several studies indicated that MPH 
inhibits the presynaptic dopamine transporter [4,5]. 
The mechanism of action includes inhibition of the 
re-uptake of norepinephrine and dopamine into the 
presynaptic neuron or an increase of their intrasynap-
tic concentrations by increasing their release into the 
extraneuronal space [6]. 
Ritalinic acid (RA), the major inactive metabolite 
of MPH, is one of the isomers of amphetamine. The 
circulating concentrations of RA greatly exceed that 
of the parent drug [7]. If MPH is given in the normal 
dosage for clinical use, the plasma concentration of RA 
reaches a maximal concentration of 10 ng/mL with a 
half-life of 2.5 hours [8]. RA is soluble in water and due 
to its small size, it readily passes the blood brain and 
testicular barriers [9].
Due to the wide use of MPH to treat ADHD, several 
studies have been conducted to evaluate its impact on 
various body biological systems in general and the re-
productive system in particular; however, most of them 
are animal studies. Chronic use of MPH decreases the 
body weights of male mice as compared to a control 
group. In addition, the weight of the testes and seminal 
vesicles decreased significantly [10]. MPH was reported 
to reduce the number of Leydig cells and serum testos-
terone levels, increase the percentage of abnormal tail 
and sperm cell morphology and the testicular intersti-
tial tissue volume, along with a reduction in fertility 
rates of the male mice in the MPH treated groups com-
pared to controls [11,12]. MPH was reported to negative-
ly affect spermatogenesis not only by reducing testicu-
lar weight and number of round spermatids but also by 
increasing apoptotic death and p53 activation [13]. 
Previous studies, mainly animal ones, investigated 
the impact of orally administrated MPH on biologi-
cal systems. However, no study assessed the effect of 
MPH or its metabolites on human sperm. This lack of 
information might be related to the young age of the 
patients, mostly prepubertal boys, to whom MPH was 
prescribed at the time the drug was approved for clini-
cal use in 1955. Nonetheless, the growing use of MPH 
in adolescents and adults who are in their reproductive 
age, and the growing rate of MPH abuse, requires an 
evaluation of the impact of MPH on male reproduction. 
The aim of the present study is to investigate the di-
rect effect of RA on human semen parameters in vitro.
MATERIALS AND METHODS
1. Ethics statement
Following the approval of the study by the Insti-
tutional Review Board (IRB) of the Cleveland Clinic 
Foundation Hospital (Reg. No. 15-435) according to the 
Declaration of Helsinki, a total of 13 semen samples 
were collected from healthy donors by masturbation 
after 2 to 3 days of abstinence. An informed, written 
consent has been obtained from each donor. 
2. Semen samples
All samples were allowed to liquefy completely for 20 
minutes at 37°C before further processing. The initial 
semen analysis was performed according to the World 
Health Organization (WHO) 5th edition [14]. Density 
gradient centrifugation was performed to isolate motile 
sperm. Given the achieved plasma concentration of 10 
ng/mL during treatment, each sample was incubated 
with different concentrations of RA (1, 10, 100, and 1,000 
ng/mL RA) and compared to a control without RA 
from the same patient. Depending on the volume of se-
men available, not all tests could be performed for each 
donor. However, a minimum of 8 samples was used.
The following inclusion criteria were applied for 
samples to be eligible for enrollment into the study: 
generally healthy males over 18 years of age who were 
willing to abstain from sexual activities for 2 to 3 days 
prior to semen collection, and normal semen analysis 
as per WHO 2010 guidelines. Subjects presenting with 
any of the following were excluded: sample of high 
viscosity semen, non-compliance with protocol require-
ments, and any abnormal semen parameter according 
to the WHO 2010 criteria.
3. Standard semen analysis 
Following liquefaction, after the sample has been 
in the incubator for 20 minutes at 37°C, the sample 
is examined for viscosity by the ease of pipetting in 
a graduated serological pipette. Viscosity is graded as 
follows: Normal viscosity: the sample can easily pass 
in the pipette and expelled easily, slight viscosity: the 
sample is not expelled easily out of the pipette, moder-
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ate: difficult to pipette and expel, high viscosity: the 
sample is a coagulum and cannot be aspirated. In the 
current study, none of our donors presented with mod-
erate or high viscosity. Hence none of the samples were 
excluded. Semen specimens were evaluated for volume, 
liquefaction, color, pH, and volume as well as sperm 
concentration, motility, and vitality as per WHO 2010 
guidelines. Motile sperm were obtained by pooling of 
semen samples prepared by double density gradient 
separation. The motile sperm were tested for the effect 
of different concentrations of RA (1, 10, 100, and 1,000 
ng/mL) on spermatozoa. 
4.  Sperm preparation by density gradient 
centrifugation
In order to evaluate the better fraction of motile 
sperm, spermatozoa were prepared by separation on a 
double density gradient by layering 2 mL each of up-
per (45%) and lower phase (90%) layer (Vitrolife, San 
Diego, CA, USA). Two mL of liquefied semen were 
layered on top. Samples were centrifuged at 300 ×g for 
20 minutes at room temperature. The resulting pellet 
was aspirated and re-suspended with 2 mL of human 
tubal fluid (HTF) medium supplemented with 2 mg/
mL human serum albumin. The final concentration 
was adjusted to 20×106 motile spermatozoa/mL and 0.5 
mL aliquots were used for sperm motility studies.
5. Human sperm motility assay
A human sperm motility assay was used to test the 
toxicity of the RA at different concentrations [15]. We 
used a computer assisted semen analyzer IVOS II, ver. 
14 (Hamilton Thorne, Beverly, MA, USA). The setting 
included a heated stage set at 37°C. Spermatozoa in 
HTF suspensions was exposed to RA at increasing con-
centrations (1, 10, 100, and 1,000 ng/mL) at 37ºC in an 
incubator in an atmosphere with 5% CO2 for 1, 2.5, 4, 
and 5 hours. After incubation, samples were vigorously 
mixed by pipetting and an aliquot of the test sample 
was placed on a MicroCell chamber and examined un-
der phase contrast at ×20 magnification for motility. 
Motion kinetic parameters (curvilinear velocity, VCL; 
amplitude of lateral head displacement, ALH; linearity, 
LIN) were recorded by computer aided semen analysis 
(CASA, IVOS II; Hamilton Thorne).
6. Vitality test
Sperm vitality was tested using the eosin–nigrosine 
stain. An amount of 0.67 g eosin Y (color index 45,380) 
and 0.9 g sodium chloride (NaCl) were dissolved in 100 
mL of purified water. Ten grams of nigrosin (color in-
dex 50,420) were added to the 100 mL of eosin Y solu-
tion. Semen samples were mixed with an equal volume 
of eosin–nigrosin suspension in a porcelain spot plate 
well or test-tube. A smear on a glass slide was made 
from each suspension and was allowed to air dry. Im-
mediately after drying, each slide was examined at 
×1,000 magnification under oil immersion. The number 
of stained (dead) or unstained (vital) cells was evalu-
ated and the percentage of vital sperm was calculated.
7.  Measurement of the oxidation reduction 
potential 
Oxidation reduction potential (ORP) levels were 
measured in sperm suspension by using the MiOXSYS 
analyzer (Aytu Bioscience, Eaglewood, CO, USA) at 0 
and 240 and 300 minutes parallel to the vitality and 
motility tests. ORP measures the transfer of electrons 
from a reductant (or antioxidant) to an oxidant. Brief-
ly, 30 mL of liquefied semen at room temperature were 
applied to the MiOXSYS sensor. The sensor was pre-in-
serted into the MiOXSYS analyzer; measurements be-
gin automatically. ORP is measured in milli-volts (mV) 
and is the integrated measure of the existing balance 
between total oxidants and reductants in a biological 
system.
Each sample was measured in triplicate, and the av-
erage values for ORP were recorded. Data were then 
normalized to sperm concentration to control for dif-
ferences in cell numbers. Thus, data are presented as 
mV/106 sperm/mL. To assess the effects of time on ORP 
measures, samples were incubated at room tempera-
ture for 0 and 120 minutes before being measured.
8. Statistical analysis
For statistical analysis, MedCalc Statistical Software, 
ver. 17.4 (MedCalc Software bvba, Ostend, Belgium) 
was used. After testing for normal distribution of the 
data by means of the Kolmogorov–Smirnov test, the 
parametric (paired-samples t-test) and non-parametric 
tests (Wilcoxon test and Kruskal–Wallis test with 
Jonckheere–Terpstra trend), respectively, were em-
ployed. Data are presented as mean±standard error of 




All semen samples underwent an initial semen 
analysis according to the WHO 5th edition. All samples 
were found eligible and no sample was required to be 
excluded.
1. Sperm motility
A total of 10 samples were evaluated for sperm mo-
tility. Samples were analyzed at different time points 
(0, 60, 150, 240, and 300 minutes) based on the half-life 
of RA in plasma. All concentrations of RA used in this 
study significantly (p<0.05) increased sperm motility 
with a maximum after 240 minutes of incubation (Fig. 
1). This increase was maintained with rising concen-
trations of up to 1,000 ng/mL. Thereafter, a decrease 
was observed at 300 minutes of incubation in treated 
samples, even though motility remained significantly 
higher compared to control. From the control to the 240 
minutes incubation point, the Jonckheere–Terpstra 
trend test indicated for all concentrations significant 
trends (p<0.05), though the Kruskal–Wallis test was 
not significant (p=0.2473 to p=0.1315). No significant 
changes were seen in sperm motion kinetic parameters.
2. Sperm vitality
A total of 13 samples were evaluated for sperm vital-
ity (Fig. 2; Supplementary Fig. 1). Since an increase in 
sperm motility was observed in 60 and 150 minutes, 
vitality would not be decreased at these time points, 
sperm vitality was instead analyzed at 3 time points 
(0, 240, and 300 minutes). A reduction in vitality was 
observed as compared to the control group without ad-
dition of RA. The addition of RA to the sperm samples 
caused sperm to retain their vitality.
3. Oxidation-reduction potential
A total of 8 samples were evaluated for ORP before 
and after exposure to RA. Samples were analyzed at 
3 time points (0, 240, and 300 minutes) after the ob-
served increase in sperm motility was observed in 60 
and 150 minutes (Fig. 3; Supplementary Fig. 2). A non-
significant trend (p=0.3125 and p=0.1953) of increase in 
ORP levels compared to the control was observed in all 












































































































Fig. 3. The impact of ritalinic acid on oxidation reduction potential.
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DISCUSSION
MPH in its various administration forms is widely 
used for treatment of ADHD in the general population, 
including those patients at reproductive age. Increas-
ing age of the treated patients and increased rates of 
MPH abuse have been reported as well [16]. The direct 
impact of MPH on human sperm and the resulting im-
pact on male reproduction is still unknown. This study 
is the first indicating that MPH metabolite, RA, has a 
temporary effect on sperm function including increased 
vitality, motility and possibly increased reactive oxygen 
species (ROS) levels as compared to controls.
Results of the current study clearly show that MPH 
main metabolite, RA, was able to increase human 
sperm motility, while sperm kinematic parameters, 
such as LIN, ALH, and VCL were not affected. In addi-
tion, vitality was maintained over time at significantly 
higher levels as compared to the control. It is also im-
portant to note that despite increased oxidative stress 
(OS) levels as measured as ORP after 240 and 300 min-
utes, respectively, these increases were not significant. 
Moreover, the impact of RA on sperm functions was 
comparable in all studied RA concentrations including 
the subclinical dose of 1 ng/mL, and the abuse equiva-
lent doses of 100 and 1,000 ng/mL. However, due to the 
fact that the actual RA concentrations in semen have 
never been reported before, concentrations used in this 
study were only based on plasma levels and has to be 
considered as a limitation of our study. 
The exact mechanism of action of MPH in ADHD 
treatment is still debatable. It is hypothesized that 
MPH acts as a catecholamine reuptake inhibitor im-
pacting mainly dopamine and norepinephrine levels. 
MPH blocks the dopamine transporter in the central 
nervous system, thus causing an increased dopamine 
concentration in the synaptic cleft [17]. In the male 
reproductive system, high concentrations of catechol-
amines including dopamine [18] and the presence of 
dopamine receptors in the sperm cell [19] including a2- 
and b-adrenergic receptors and the dopamine type 2 
receptor in testis, as well as spermatogenic cells and 
sperm cells have been described [20]. Catecholamines 
were reported to impact sperm cell motility [21]. While 
evaluating the impact of dopamine on sperm motil-
ity, Urra et al [19] exposed human sperm to differ-
ent dopamine concentrations. An inhibition of total 
sperm motility and progressive motility was observed 
after incubation for 1, 3, and 6 hours at a dopamine 
concentration of 1 mM. Nevertheless, exposing sperm 
to dopamine in the absence and presence of a specific 
dopamine transporter inhibitor, the dopamine-induced 
inhibition of total sperm motility was partially re-
versed. Thus, the temporary increase in sperm motil-
ity observed in the current study corresponding to the 
MPH half-life may be explained by the inhibition of 
the dopamine uptake inhibition.
The observed increased motility cannot be attributed 
to decreased OS levels as measured by ORP since these 
slightly, but not significantly, increased. At this stage, 
it can also only be speculated whether this increased 
ROS activity is due to increased metabolic activity of 
the spermatozoa or simply caused by the elimination of 
protective antioxidants present in the seminal plasma. 
Excessive ROS production that impairs the fine redox 
balance between oxidants and anti-oxidants (enzymatic 
and non-enzymatic) yield OS. In turn, OS has a well-
established deteriorating effect on sperm function 
including reduced sperm motility, decreased ability of 
spermatozoa to adhere to the oocyte [22], to undergo 
capacitation [23] as well as OS-induced DNA damage, 
mainly DNA fragmentation [24]. Previous studies re-
ported that a large percentage of male factor infertility 
is due to OS-mediated sperm damage [25,26]. In addi-
tion, several extrinsic factors such as smoking [27,28] or 
varicocele [29] may cause OS.
On the other hand, naturally generated low ROS 
levels are major role players in male reproductive 
physiologic processes such as spermatogenesis and 
the triggering of sperm capacitation. Ultimately, the 
molecular processes involved in sperm binding to the 
zona pellucida are also mediated by hydrogen peroxide. 
Likewise, ROS in low levels are important for proper 
sperm motility [24]. ROS, in general, are essential for 
proper spermatogenic mechanisms to occur, and hy-
drogen peroxide, in particular, stimulates acrosomal 
reaction, tyrosine phosphorylation and hyperactivation 
in the male germ cell. The latter, in turn is a direct 
expression of changes taking place in the sperm kine-
matic parameters VCL (>150 µm/s), LIN (<50%), and 
ALH (>7 µm). Considering that these parameters did 
not change during the incubation with MPH, however, 
one can assume that MPH did not stimulate intrinsic 
ROS production which, in turn, would trigger capaci-
tation, sperm hyperactivation and acrosome reaction. 
On the other hand, sperm exposed to dopamine and 
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norepinephrine after facilitating capacitation with 
heparin were reported to have a dose-dependent effect 
on the acrosome integrity [19,20] implying that sperm 
would not be able to fertilize the oocyte by the time it 
will reach it as capacitation and/or the acrosome reac-
tion are prematurely triggered.
A potential application of the observed impact of RA 
(or any other dopamine reuptake inhibitor) on sperm 
cells may be as a motility enhancer. This would be of 
particular interest in patients with asthenozoospermia 
or during various fertility treatment procedures such 
as intra-uterine insemination (IUI). IUI is often a first 
line treatment in patients with adequate sperm num-
bers since it is minimally invasive and far less expen-
sive when compared to in-vitro fertilization. It is used 
when there is only mildly reduced sperm count, motil-
ity or morphology as well as in cases of unexplained in-
fertility. In this procedure, the sperm avoids the hostile 
vaginal environment and the need to pass through the 
uterine cervix. However, the transport to the fallopian 
tube and more importantly fertilization of the egg re-
mains. Hence, an increased sperm motility observed af-
ter the use of RA may be used to increase motility and 
therefore potentially increase the effectiveness of IUI. 
However, before using RA during fertility treatments, 
its impact on sperm capacitation, acrosome reaction 
and sperm DNA must be determined. These processes 
are major role players in the fertilizing competence of 
sperm and are essential to enable the sperm to pen-
etrate the oocyte and cause fertilization [30].
The current study has some limitations. The first is 
the small study sample of the evaluated parameters. 
Another limitation is the fact that only selected sperm 
parameters including vitality, total motility, VCL, 
ALH, LIN, and ORP were measured. However, the fact 
that despite the small sample significant differences 
were observed between the study groups reflects the 
substantial effect of RA on sperm function parameters. 
CONCLUSIONS
In conclusion, RA significantly increased sperm mo-
tility and maintained vitality over a long incubation 
period. This may allow its in vitro use to improve sperm 
motility in cases of patients with asthenozoospermia. 
However, it is unknown what effects RA has on other 
sperm functional characteristics such as: capacitation, 
acrosome reaction, intrinsic ROS production and sperm 
nuclear DNA fragmentation. Further investigation is 
required prior to considering its clinical use.
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